SMILE techniques less disruptive

Article

Corneal biomechanical stability is better, less affected by flapless refractive procedure

The study included 60 eyes of 30 patients divided into two groups. The same femtosecond laser (VisuMax 500, Carl Zeiss Meditec) was used to create the LASIK flaps and the lenticule for the SMILE procedure, and the LASIK ablations were performed using a single excimer laser platform (WaveLight Allegretto, Alcon, Fort Worth, Texas, USA).

All LASIK flaps and SMILE caps had an attempted thickness of 90 μm. Corneal biomechanics were assessed using the Ocular Response Analyzer (ORA, Reichert, Munich, Germany) to measure corneal hysteresis (CH) and corneal resistance factor (CRF) at three months preoperatively and three months postoperatively.

Mean percent change in CH was –6.7% in the SMILE group and –17.4% in the femto-LASIK group. Mean percent change in CRF was –9.7% for the SMILE group and –22% for the femto-LASIK group. The reduction in CH did not correlate with the amount or percentage of corneal tissue removed nor with the optical zone or patient age.

"SMILE is a one-step, non-ablative corneal refractive procedure in which a lenticule of tissue is cut by the femtosecond laser and removed through a small incision," explained Dr Abdalla, cornea and refractive surgery senior fellow, Cornea Centre, Alexandria, Egypt. "This technique avoids recognized flap complications, including postoperative discomfort and dry eye, and as a flapless procedure, we consider SMILE the laser vision correction procedure of choice for patients involved in contact sports.

"In addition, based on our study, SMILE appears to offer better biomechanical stability than the flap-based procedure," continued Dr Abdalla. "However, further studies are warranted to confirm our findings, including in a larger patient population and ideally using better methods to evaluate corneal biomechanics."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.